How ADCs Transform Cancer Treatment
Antibody-drug conjugates (ADCs) are reshaping cancer treatment by uniting monoclonal antibodies with cancer drugs, reducing chemotherapy side effects and accelerating oncology advancements. Breakthroughs in linker technology expand ADC use, enhancing options for drug-resistant cancers. As the field evolves, ADCs promise superior clinical outcomes and economic growth, heralding a new era in personalized cancer therapy. Revolutionizing […]